Literature DB >> 19931734

Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation.

Jody Mitchell1, Graeme C M Smith, Nicola J Curtin.   

Abstract

PURPOSE: Radiation-induced DNA double strand breaks (DSBs) are predominantly repaired by nonhomologous end joining (NHEJ), involving DNA-dependent protein kinase (DNA-PK). Poly(ADP-ribose) polymerase-1 (PARP-1), well characterized for its role in single strand break repair, may also facilitate DSB repair. We investigated the activation of these enzymes by differing DNA ends and their interaction in the cellular response to ionizing radiation (IR). METHODS AND MATERIALS: The effect of PARP and DNA-PK inhibitors (KU-0058684 and NU7441) on repair of IR-induced DSBs was investigated in DNA-PK and PARP-1 proficient and deficient cells by measuring gammaH2AX foci and neutral comets. Complementary in vitro enzyme kinetics assays demonstrated the affinities of DNA-PK and PARP-1 for DSBs with varying DNA termini.
RESULTS: DNA-PK and PARP-1 both promoted the fast phase of resolution of IR-induced DSBs in cells. Inactivation of both enzymes was not additive, suggesting that PARP-1 and DNA-PK cooperate within the same pathway to promote DSB repair. The affinities of the two enzymes for oligonucleotides with blunt, 3' GGG or 5' GGG overhanging termini were similar and overlapping (K(d)(app) = 2.6-6.4nM for DNA-PK; 1.7-4.5nM for PARP-1). DNA-PK showed a slightly greater affinity for overhanging DNA and was significantly more efficient when activated by a 5' GGG overhang. PARP-1 had a preference for blunt-ended DNA and required a separate factor for efficient stimulation by a 5' GGG overhang.
CONCLUSION: DNA-PK and PARP-1 are both required in a pathway facilitating the fast phase of DNA DSB repair.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19931734     DOI: 10.1016/j.ijrobp.2009.07.1722

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  26 in total

1.  Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.

Authors:  Niklaus G Schaefer; Engles James; Richard L Wahl
Journal:  Nucl Med Commun       Date:  2011-11       Impact factor: 1.690

2.  PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis.

Authors:  I Rybanska; O Ishaq; J Chou; M Prakash; J Bakhsheshian; D L Huso; S Franco
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

3.  Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.

Authors:  Sumin Han; J Chad Brenner; Aaron Sabolch; Will Jackson; Corey Speers; Kari Wilder-Romans; Karen E Knudsen; Theodore S Lawrence; Arul M Chinnaiyan; Felix Y Feng
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

Review 4.  Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer.

Authors:  Zeeshan Ramzan; Ammar B Nassri; Sergio Huerta
Journal:  World J Gastrointest Oncol       Date:  2014-07-15

5.  FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1.

Authors:  Xi Wu; Zizheng Dong; Chao J Wang; Lincoln James Barlow; Valerie Fako; Moises A Serrano; Yue Zou; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

6.  Radiation damage and radioprotectants: new concepts in the era of molecular medicine.

Authors:  M I Koukourakis
Journal:  Br J Radiol       Date:  2012-01-31       Impact factor: 3.039

Review 7.  Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

Authors:  Frédérique Mégnin-Chanet; Marc A Bollet; Janet Hall
Journal:  Cell Mol Life Sci       Date:  2010-08-20       Impact factor: 9.261

8.  Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma.

Authors:  Sabine Mueller; Samhita Bhargava; Annette M Molinaro; Xiaodong Yang; Ilan Kolkowitz; Aleksandra Olow; Noor Wehmeijer; Sharon Orbach; Justin Chen; Katherine K Matthay; Daphne A Haas-Kogan
Journal:  Anticancer Res       Date:  2013-03       Impact factor: 2.480

Review 9.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 10.  Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Authors:  N J Curtin
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.